Patent 11759504 was granted and assigned to Ascendis Pharma on September, 2023 by the United States Patent and Trademark Office.
The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.